Steven Loo-Yong-Kee presents Artisan Bio's STAR-CRISPR™ system for optimized gene editing in cell therapy, with a focus on the genetifc modification of T cells for cancer immunotherapy.

Cell therapy is an emerging field with great promise for the treatment of various diseases. One of the most exciting areas of cell therapy is the use of T cells that have been genetically modified to recognize and kill cancer cells. While the use of T cells for cancer immunotherapy has tremendous promise, there is still room for improvement. The efficiency, expansion, and functionality of T cells can be enhanced by genetic modification using the STAR-CRISPR™ system.

Artisan Bio is a biotechnology company focused on developing a CRISPR-mediated editing platform to improve the efficacy and safety of cell therapy products. In this webinar, we will provide a comprehensive overview of Artisan Bio’s STAR-CRISPR™ system, which is designed to improve the specificity and efficiency of gene editing for cell therapies. We will explain the system’s key components and how we are using a risk-based approach to optimize and validate the editing platform. The webinar will focus on Artisan Bio’s approach to building T cell OS/APPS through iterative improvements to achieve best-in-class editing capabilities and improved cell health metrics.

Key Topics Include:

  • Learn about Artisan Bio’s proprietary high-performance STAR-CRISPR™ system for improving the specificity and efficiency of gene editing for cell therapies.
  • Explore Artisan Bio’s risk-based, systems approach to technology development, including how to implement Design of Experiments (DoE) and Quality by Design (QbD) principles to optimize and validate any process.
  • Case study of the application of QbD to Artisan Bio’s STAR-CRISPR™ platform to edit T cells for cancer immunotherapy with preliminary data showing improved efficacy, expansion, and functionality.

Click to watch the webinar recording. To view the presentation full screen, click the square icon in the bottom-right corner of the video viewer.

Resources

#ExpertAnswers: Steven Loo-Yong-Kee on CRISPR-Edited T Cells

Play
Access the Q&A Report

To retrieve a PDF copy of the presentation, click on the link below the slide player. From this page, click on the “Download” link to retrieve the file.

Presenters

Steven Loo-Yong-Kee, ;MEng

Steven Loo-Yong-Kee, MEng

Scientist II
Cell Biology and Immunology
Artisan Bio

Steven is a chemical engineer with over 7 years of experience in the cell and gene therapy industry, specializing in immunotherapy products. He has played a critical role in the development of Artisan's T cell and iPSC editing platforms, including process development, optimization, and technology transfer. He is also a founding member of the company's internal DoE core, offering insights into QbD methodologies.

Production Partner

STEMCELL Technologies Inc.

STEMCELL Technologies provides specialized cell culture media, cell isolation products, and reagents for your cell therapy and drug discovery research. Our ethically sourced human primary cell portfolio includes products from peripheral blood, cord blood, and bone marrow.

VIEW PROFILE
STEMCELL Technologies Inc.

Additional Content From STEMCELL Technologies Inc.

Related Content